Clinical Trial Search

Primary: Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy — 1.96; 1.98; 2.45; 1.84 units on a scale — p=<0.01

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 of Administration — 6.7; 5.2 number of SBM per week — p=0.020

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 — 3.1; 4.4 SBMs/week — p=0.007

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 — 3.6; 5.0 SBMs/week — p=0.003

Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week

Primary: Change From Baseline in Colonic Transit Time (CTT) — -727; -15; 366 minutes

Primary: Change From Baseline to End of Study — 64; 18.5 Percentage of participants

Primary: Colonic Compliance — 16.60; 16.50 mm Hg

Primary: Bowel Movement (BM) Within 3 Days of Surgery — 29; 32 Participants — p=0.41

Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.40; 2.58 Number of SBMs/week

Primary: Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing. — 8; 5; 4; 6 participants

Primary: Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym) — -0.22; -0.29 units on a scale — p=<0.05

Primary: Overall Responder 9/12 Weeks — 18.6; 16.8; 19.0; 10.7 % of Overall Responder 9/12 weeks

Primary: Number of Spontaneous Bowel Movements in Patients With Multiple Sclerosis (MS)-Associated Constipation Per Day. — 3.4; 3.2 spontaneous bowel movements

Primary: Colonic Transit at 24 Hours — 2.68; 3.12; 1.93 units on a scale — p=0.059

Primary: Efficacy, Measured by the Average Number of Spontaneous Bowel Movements (SBMs) Per Week — 4.85; 1.40; 3.81; 2.41 spontaneous bowel movements

Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour

Primary: Percentage of 12-Week CSBM Overall Responders — 4.7; 13.4; 95.3; 86.6 percentage of participants — p=< 0.0001

Primary: Change From Baseline in Weekly Abdominal Pain Score Over the 12-Week Treatment Period: DR1 or IR vs. Placebo — -1.370; -1.938; -1.667; -1.656 score on a scale — p=0.0839

Primary: Number of Participants With Adverse Events — 3; 6; 2; 6 Participants

Primary: Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period — 17.0; 17.8 percentage of subjects — p=0.9002

Primary: Mean Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week Over the 4 Weeks Treatment Period — 1.9; 5.2 CSBMs per week — p=<0.0001

Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours

Primary: Complete Spontaneous Bowel Movement (CSBM) Overall Responder — 46; 42; 7 participants — p=<0.0001

Primary: Treatment Recovery — 33; 19 participants — p=0.024

Primary: Change in Methane Production — 10645; 14635 parts per million*minutes

Primary: Number of Spontaneous Bowel Movements (SBMs) Within 1 Week — 4.6; 4.0 number of SBMs — p=0.1290

Primary: Number of Participants With a Complete Resolution at the Final Visit — 36; 23 Participants — p=0.0595

Primary: Change From Baseline in 8-Week SBM Frequency Rate (SBMs/Week) — 1.474; 2.799; 3.382 Number of SBMs per week — p=0.0035

Primary: Whole Gut Transit Time